Form 4: Cytokinetics CEO Robert Blum Reports Stock Transactions to Satisfy Tax Obligations

Cytokinetics' CEO, Robert Blum, reports the withholding of company shares to cover tax obligations related to vesting Restricted Stock Units.

Summary

• On March 4, 2024, Robert I Blum, President & CEO and Director of Cytokinetics Inc, had 25,341 shares of common stock withheld at a price of $67.68 to cover tax obligations.
• Following this transaction, Mr. Blum directly owns 416,456 shares of Cytokinetics common stock.
• On March 6, 2024, a further 16,725 shares were withheld at $66.88, resulting in direct ownership of 399,731 shares.
• Mr. Blum also indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and another 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions related to tax obligations, with no inherent positive or negative implications for the company's performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates transactions related to tax obligations from vested equity.

Stakeholder Impact

• The transactions have a minor dilutive effect on existing shareholders due to the shares being withheld, but this is a standard practice for equity compensation.

Key Dates